Tirzepatide has helped many trial participants lose weight, and some studies have measured benefits beyond the scale. In one large obesity trial, average weight loss after 72 weeks ranged from 15% to nearly 21%, depending on the assigned dose, compared with 3% on placebo. The average conceals people who lost much less or stopped because of side effects. Stomach side effects, medical history and what happens after treatment stops matter just as much as the headline number (SURMOUNT-1 trial: https://pubmed.ncbi.nlm.nih.gov/35658024/).
People sometimes call tirzepatide a healing peptide. It is a prescription medicine with evidence for specific conditions, not a general tissue-repair treatment. Its best tested uses involve obesity and type 2 diabetes. Trials also address obstructive sleep apnea and a particular form of heart failure. Research into fatty liver disease is promising but still developing. Published interviews and a case report show how some people experienced treatment. Their experiences cannot predict another person's result.
What is tirzepatide?
Tirzepatide is a manufactured peptide, a chain of amino acids, given by injection once a week in the trials. It activates two receptors that respond to gut hormones called GIP and GLP-1. These signals help regulate blood sugar and appetite. The first laboratory paper tested receptor activity in cells and glucose responses in mice, then reported short early studies in people. It did not demonstrate that tirzepatide heals nerves or damaged organs (original mechanism and early human study: https://pubmed.ncbi.nlm.nih.gov/30473097/).
In the United States the same active substance is sold under different brand names for different approved uses. The current official Zepbound prescribing information covers long-term weight reduction in eligible adults and moderate to severe obstructive sleep apnea in adults with obesity. It also describes important risks and restrictions (official prescribing information: https://pi.lilly.com/us/zepbound-uspi.pdf). Local approvals and access vary. Tirzepatide works through GIP and GLP-1 receptors. It is distinct from the growth-hormone peptides in our ipamorelin research article and CJC-1295 review.
The 2,539-person weight-loss trial
SURMOUNT-1 assigned 2,539 adults with obesity, or overweight plus a weight-related condition, to tirzepatide or placebo. Participants did not have diabetes, and every group also received lifestyle advice. After 72 weeks, mean weight loss was 15.0% with the 5 mg group, 19.5% with 10 mg, 20.9% with 15 mg, and 3.1% with placebo (original trial: https://pubmed.ncbi.nlm.nih.gov/35658024/). A 20% average is substantial, but it hides the spread of individual responses. The trial cannot tell a particular reader what they will lose, nor whether weight will stay off without continued treatment.
The follow-up answers part of the durability question. Among participants with prediabetes at entry, progression to type 2 diabetes over 176 weeks was lower in the tirzepatide groups than with placebo. Weight loss was also largely maintained while treatment continued. This was an extension of SURMOUNT-1, not a new independent trial, and it studied a selected group under regular follow-up (SURMOUNT-1 extension: https://pubmed.ncbi.nlm.nih.gov/39536238/). A lower rate of new diabetes in that setting should not be described as a permanent cure.
Later obesity trials asked whether the results held in other groups and after treatment stopped. SURMOUNT-2 enrolled 938 adults with type 2 diabetes; mean weight loss at 72 weeks was 12.8% and 14.7% on the two tirzepatide doses versus 3.2% on placebo (https://pubmed.ncbi.nlm.nih.gov/37385275/). SURMOUNT-3 enrolled people who had already lost at least 5% after an intensive lifestyle program, then tested added tirzepatide against placebo (https://pubmed.ncbi.nlm.nih.gov/37840095/). SURMOUNT-4 gave everyone tirzepatide first, then randomly assigned them to continue it or switch to placebo. Over the next 52 weeks, the continuation group lost another 5.5% on average, while the switch group regained 14.0% from the point of randomization (https://pubmed.ncbi.nlm.nih.gov/38078870/). Regain after stopping is an important part of the story. A 2026 maintenance trial followed people who had already lost weight during 60 weeks of tirzepatide, then assigned them to continue their tolerated dose, reduce to 5 mg or switch to placebo. By week 112, average weight loss from the original starting point was 21.9%, 16.6% and 9.9%, respectively. These results come from a selected group that completed the lead-in, and some participants needed rescue treatment (SURMOUNT-MAINTAIN: https://pubmed.ncbi.nlm.nih.gov/42119587/).
SURMOUNT-5 compared tirzepatide directly with semaglutide in 751 adults with obesity but without diabetes. At 72 weeks, mean weight loss was 20.2% versus 13.7%. The study was open label, and its primary outcome was weight, not heart attacks or lifespan (https://pubmed.ncbi.nlm.nih.gov/40353578/). Trials in Chinese and Japanese adults also found greater weight loss than placebo, adding useful population-specific evidence (SURMOUNT-CN: https://pubmed.ncbi.nlm.nih.gov/38819983/; SURMOUNT-J: https://pubmed.ncbi.nlm.nih.gov/40031941/).
How the diabetes trials compare
Blood sugar control is measured partly by HbA1c, which reflects average glucose over the previous few months. The original phase 2 diabetes study compared tirzepatide with placebo and dulaglutide and found stronger glucose lowering at higher doses, alongside more digestive complaints (https://pubmed.ncbi.nlm.nih.gov/30293770/). The larger SURPASS program then tested it in different treatment settings:
- SURPASS-1 compared tirzepatide with placebo in 478 people managing type 2 diabetes without another glucose-lowering medicine (https://pubmed.ncbi.nlm.nih.gov/34186022/).
- SURPASS-2 compared it with semaglutide 1 mg in 1,879 people. At 40 weeks, all three tirzepatide groups had lower average HbA1c, and weight loss was greater, though this was not a comparison with the later obesity dose of semaglutide (https://pubmed.ncbi.nlm.nih.gov/34170647/).
- SURPASS-3 and SURPASS-4 compared it with insulin degludec and insulin glargine, respectively, in people whose diabetes needed more treatment (https://pubmed.ncbi.nlm.nih.gov/34370970/; https://pubmed.ncbi.nlm.nih.gov/34672967/).
- SURPASS-5 tested tirzepatide added to basal insulin against placebo added to basal insulin; SURPASS-6 compared adding tirzepatide with adding mealtime insulin lispro (https://pubmed.ncbi.nlm.nih.gov/35133415/; https://pubmed.ncbi.nlm.nih.gov/37786396/).
- Japanese SURPASS J-mono compared tirzepatide with dulaglutide, while J-combo studied it alongside different oral diabetes drugs. An Asia-Pacific study compared tirzepatide with insulin glargine (https://pubmed.ncbi.nlm.nih.gov/35914543/; https://pubmed.ncbi.nlm.nih.gov/35914542/; https://pubmed.ncbi.nlm.nih.gov/37231074/).
A newer trial, SURPASS-EARLY, followed 794 people with recently diagnosed type 2 diabetes who were taking metformin. After two years, average HbA1c had fallen 1.99 percentage points with tirzepatide and 1.32 points with intensified usual care. It was open label, so participants and clinicians knew the assigned treatment (https://pubmed.ncbi.nlm.nih.gov/42184419/).
The diabetes trials enrolled different groups and used different comparisons. Across them, tirzepatide generally lowered average glucose and weight more than the comparator. They do not establish that someone can stop all diabetes care. In a later cardiovascular outcomes trial involving more than 13,000 people with type 2 diabetes and established artery disease, tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack or stroke. It did not prove superiority on that primary outcome (SURPASS-CVOT: https://pubmed.ncbi.nlm.nih.gov/41406444/).
Sleep apnea, heart failure and liver disease
Two SURMOUNT-OSA trials assigned 469 adults with obesity and moderate to severe sleep apnea to tirzepatide or placebo for 52 weeks. One trial included people not using positive airway pressure; the other included users of that treatment. The number of breathing interruptions per hour fell more with tirzepatide in both trials. Sleep-related patient reports also improved. These findings support a specific sleep-apnea use in eligible adults, rather than a claim that the medicine cures every sleep problem (https://pubmed.ncbi.nlm.nih.gov/38912654/).
SUMMIT studied 731 people with obesity and heart failure with preserved pumping function. A combined outcome of cardiovascular death or worsening heart failure occurred in 9.9% assigned tirzepatide and 15.3% assigned placebo. Patients also reported better heart-failure health status after 52 weeks. The combined outcome was driven largely by fewer worsening-heart-failure events; cardiovascular deaths alone were too few to establish a reduction (https://pubmed.ncbi.nlm.nih.gov/39555826/).
In SYNERGY-NASH, 190 people with biopsy-confirmed inflammatory fatty liver disease and moderate or severe fibrosis were randomized to tirzepatide or placebo. After 52 weeks, the primary biopsy outcome, resolution of inflammation without worsening fibrosis, occurred in 44% to 62% across the tirzepatide groups versus 10% on placebo. That is a tissue finding, but the study was too small and short to prove prevention of cirrhosis or liver death (https://pubmed.ncbi.nlm.nih.gov/38856224/). A kidney analysis of SURPASS-4 found encouraging changes in kidney measurements; it was a secondary analysis, so it should not be sold as proof of kidney regeneration (https://pubmed.ncbi.nlm.nih.gov/36152639/).
What patients said, and one published case
Researchers interviewed 86 people after SURMOUNT-4. Participants described appetite control, more energy and clothes fitting differently; some also described gastrointestinal side effects. All interviewees had received tirzepatide during the trial's initial phase. The interview sample may favor people willing to speak about a good experience, so these accounts add texture to the trial numbers without replacing them (original exit-interview study: https://pubmed.ncbi.nlm.nih.gov/39987302/).
One published case report followed a man in his forties with a spinal cord injury who had struggled with weight despite dietary work and adapted exercise. His recorded weight went from 115.7 kg to 100.7 kg after a year of tirzepatide alongside continued care. He reported mild heartburn. The report cannot separate the medicine from every other change in his life, and one person is not a trial (original case report: https://www.nature.com/articles/s41394-025-00699-w). His experience is encouraging, but it cannot tell another person what will happen.
Side effects and who should avoid it
The official label lists nausea, diarrhea, vomiting, constipation and other digestive effects among common problems. It warns about severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis and serious allergic reactions. Tirzepatide can increase the risk of low blood sugar when combined with insulin or certain other diabetes drugs. Its boxed warning concerns thyroid C-cell tumors seen in rats; whether this risk applies to humans is unknown. People with a personal or family history of medullary thyroid cancer or MEN2 should not use it. The label also addresses pregnancy, delayed absorption of oral medicines and a temporary drop in reliability of oral contraceptives after starting or increasing treatment (official prescribing information: https://pi.lilly.com/us/zepbound-uspi.pdf).
A peptide sold online under the same name is not automatically the studied product. Trial results depend on a known preparation, medical screening and follow-up. Anyone considering treatment should discuss their condition, other medicines and the possibility of long-term use with a qualified clinician. The strongest evidence supports specific metabolic and sleep-apnea outcomes. It does not show general healing of every tissue, effortless weight maintenance after stopping, or freedom from side effects.
